Page last updated: 2024-12-07

allotrap

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

allotrap: RN refers to Allotrap 07; small synthetic peptides derived from the alpha1 helix of the heavy chain of HLA class I proteins; inhibits human T cell responses in vitro; prolongs allograft survival in rats and mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132929
MeSH IDM0243830

Synonyms (8)

Synonym
151232-75-6
l-tyrosine, n-(n-(n(2)-(n-(n(2)-(n(2)-(n-(n-(n-l-arginyl-l-alpha-glutamyl)-l-seryl)-l-leucyl)-l-arginyl)-l-asparaginyl)-l-leucyl)-l-arginyl)glycyl)-
peptide bc-1nl
allotrap
DTXSID50164742
(2s,8s,11s,14s,17s,20s,23s,26s)-14-(2-amino-2-oxoethyl)-26-((s)-2-amino-5-guanidinopentanamido)-8,17-bis(3-guanidinopropyl)-2-(4-hydroxybenzyl)-23-(hydroxymethyl)-11,20-diisobutyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazanonacosanedioic a
PD161705
AKOS040746539

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Oral administration of RDP58 significantly decreased the incidence of diarrhea and improved the survival rates of mice treated with toxic doses of CPT-11 or 5-fluorouracil."( Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity.
Belmar, N; Buelow, R; Fong, T; Huang, L; Zhao, J, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" In addition, the data suggest that the D2702 isomer is more potent than the L-isomer in vivo and may allow reduced dosage or frequency of administration."( Both L- and D-isomers of allotrap 2702 prolong cardiac allograft survival in mice.
Buelow, R; Gao, L; Woo, J, 1996
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (31.03)18.2507
2000's19 (65.52)29.6817
2010's1 (3.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.96 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (10.34%)5.53%
Reviews4 (13.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (75.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]